Close Menu
    What's Hot

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026

    US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

    August 13, 2026

    Editor’s Letter – Volume 2, Issue 8, August 2026

    August 12, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Annuity Sales Set New Quarterly Record in Second Quarter

      August 3, 2026

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Long COVID and Reinfection Risk

    Mortality April 13, 2023By Mike Fasano
    Long Covid
    Share
    Twitter LinkedIn Email

    As we enter the 4th year of the COVID-19 pandemic and as the number of infected survivors grows ever larger, attention is increasingly turning to the risks of long COVID and reinfection.

    Characteristics of Long COVID

    Most patients totally recover from acute COVID within 3 to 4 weeks after onset of infection. Long COVID has been reported in 10% to 30% of those with COVID-19,1 and in some studies, even more. It is more common in women, non-whites, hospitalized patients and those with a COPD and/or smoking history. The World Heath Organization characterizes Long COVID, or Post COVID-19 Syndrome, as being associated with:

    • Individuals with a history of probable or confirmed SARS-CoV-2 infection (the virus that causes COVID-19) who experience symptoms impacting everyday life, such as fatigue, shortness of breath and cognitive dysfunction; and

    • Symptoms that usually are present 3 months from the onset of acute COVID-19, that last for at least 2 months and can’t be explained by an alternative diagnosis.

    Interestingly, most with post-COVID syndrome are PCR negative, i.e., they have biologically recovered from acute COVID.2 Approximately 25% of Americans with long COVID report significant activity limitations.3

    Reinfection Risk

    Those infected more than once with SARS-CoV-2 have a higher risk of experiencing diseases associated with long COVID. However, the severity of disease in reinfected people appears to be relatively mild in comparison to those infected only once. A recent V.A. study compared 40,947 people with 2 or more SARS-CoV-2 infections with 443,588 people with only one infection, measuring excess burden and hazard ratios 6 months after reinfection.4

    Excess Burden and Hazard Ratios in reinfected versus singly infected people was as follows:

    Excess Burden and Hazard Ratios for specific impairment groupings measured were as follows:

    Although people with multiple SARS-CoV-2 infections clearly have a higher incidence of respiratory, cardiovascular and neurologic impairments, the severity of the reinfection related impairments is less than that associated with primary infection. A study published in the New England Journal of Medicine (NEJM) found that people experiencing a single infection only experienced severe, critical or fatal disease at more than 10 times the rate of those experiencing multiple infections.5

    The NEJM study was based on a younger, healthier cohort of subjects and therefore not entirely representative of the larger COVID positive population. Nevertheless, the comparative data is directionally instructive:

    Severity of Reinfection versus Primary Infection

    Number with Disease Outcome/Total in Study:

    Conclusions

    We continue to learn more about the long-term risks of COVID-19, but more is still unknown than known. We know that the risk for hospitalized patients is greater, more so for ICU patients. Comorbidities matter and increase risk, particularly COPD and other respiratory impairments. Reinfection increases the risk of impairments, but with diminished potency. We will continue to follow and report on the evolving research.

    Mike Fasano is CEO at Fasano Associates


    Footnotes:

    1Nashville Chest, 2022, Oct 16-19

    2Clinical Research & Reviews, 15(3), 869-875

    3CDC Survey, Sep. 14-26, 2022

    4https://news.feinberg.northwestern.edu/2020/12/04/new-drug-connects-dots-that-cause-clots-in-covid-19-patients/

    5New England Journal of Medicine 2021; 385:2487-24-89

    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - April Clinical Mortality Commentary Volume 2 Issue 4 - April 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Organ Transplant Improvements Test Life Expectancy Assessment Models

    July 8, 2026By Mark McCord

    From Policy Ambition to Operational Reality: Building the Foundations of the UK’s Next Pensions Era

    June 24, 2026By Peter Roos

    The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

    June 10, 2026By Mark McCord

    Shaping the Future of Health Insurance Through Innovation and Analytics

    June 10, 2026By Jessica Plewes and Lisa Balboa
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.